期刊文献+

异环磷酰胺、鬼臼乙叉甙、卡铂方案治疗晚期非小细胞肺癌的疗效观察 被引量:2

Ifosfamide/etoposide/carboplatin chemotherapy in the treatment of patients with advanced non-small cell lung cancer
下载PDF
导出
摘要 目的 观察异环磷酰胺、鬼臼乙叉甙、卡铂 (IEC)方案治疗晚期非小细胞肺癌的疗效和毒副反应。方法  3 3例晚期非小细胞肺癌患者接受IEC方案化疗。观察全组患者的近、远期疗效及毒副反应。结果 全组患者PR 7例 ,NC 2 4例 ,PD 2例 ,有效率为 2 1.2 % (7/3 3 ,95 %CI :7.3 %~ 3 5 .1% ) ;中位生存期 7.8月(95 %CI :6.2~ 9.4月 ) ;1年生存率为 2 0 .0 % (95 %CI :6.0 %~ 3 4.0 % )。主要毒副反应为较严重的血液学毒性 ,Ⅲ~Ⅳ度白细胞减少、血小板减少及血红蛋白减少发生率分别为 5 1.5 % (17/3 3 )、18.2 % (6/3 3 )和 3 0 .3 %(10 /3 3 )。 60岁以上组Ⅲ~Ⅳ度白细胞减少发生率 (P =0 .0 2 4)和血小板减少发生率 (P =0 .0 3 7)明显高于 60岁以下组。结论 IEC方案对晚期非小细胞肺癌有效 ;主要毒副反应为较严重的血液学毒性 ,尤其高发于老年人 ,因此对于老年患者最好在G CSF或GM Objective To investigate the efficacy and toxicity of ifosfamide, etoposide, and carboplatin (IEC) regimen in the treatment of patients with advanced non small cell lung cancer. Methods Thirty three patients with advanced non small cell lung cancer were treated with IEC regimen, which consisted of ifosfamide 2.0?g/m 2(patients with age>70 years: 1.3?g/m 2), IV D1 3; etoposide 130?mg/m 2, IV D1 3; carboplatin 300?mg/m 2, IV D1, repeated every four weeks. Results Of the 33 patients, 7 cases got partial response, 24 had stable diseases, and 2 had progressive diseases, and the overall response rate was 21.2% (7/33,95% CI: 7.3% to 35.1%). The median survival and 1 year survival rate were 7.8 months (95% CI: 6.2 to 9.4 months) and 20.0%(95% CI: 6.0% to 34.0%) respectively. Main adverse effects were severe hematologic toxicities. The frequency of leukopenia,thrombocytopenia and anemia with grade Ⅲ and grade Ⅳ was 51.5% (17/33), 18.2%(6/33) and 30.3%(10/33) respectively. There was significantly higher frequency of leukopenia (P=0.024) and thrombocytopenia (P=0.037) with grade Ⅲ and grade Ⅳ in patients with age≥60 years than those with age <60 years. Conclusion IEC is an effective regimen in the treatment of patients with advanced non small cell lung cancer. Main adverse effects are severe hematologic toxicities, which are more significant in elderly patients. It is necessary to apply G CSF or GM CSF protection to avoid severe myelosuppression for elderly patients.
出处 《中国肺癌杂志》 CAS 2002年第3期198-200,共3页 Chinese Journal of Lung Cancer
关键词 异环磷酰胺 鬼臼乙叉甙 卡铂 非小细胞肺癌 化学疗法 NSCCC 毒副反应 Non small cell lung cancer Chemotherapy Ifosfamide Etoposide Carboplatin
  • 相关文献

参考文献9

  • 1[1]Minna JD, Pass H, Glatstein E, et al. Cancer of the lung. In: DeVita V, Hellman S, Rosenberg SA ed. Cancer principles and practice of oncology. Philadelphia: Lippincott,1989.591-705.
  • 2[2]Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet,1993,342(8862)∶19-21.
  • 3[3]Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest,1994,106(3)∶861-865.
  • 4[4]Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Group Study. J Clin Oncol,1986,4(5)∶702-709.
  • 5[5]Bonomi PD, Finkelstein PM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage Ⅳ non-small cell lung cancer. A study of the Eastern Cooperative Oncology Group. J Clin Oncol,1989,7(11)∶1602-1613.
  • 6[6]Rigas JR, Kris MG, Roth JA, et al. New chemotherapeutic agents in lung cancer. In: Lung Cancer. 1st ed. Boston: Bianckwill Scientisic Publications,1993.252-269.
  • 7[7]Preti P, Poggi G, Cuomo AM, et al. Phase Ⅱ study with ifosfamide, carboplatin, etoposide (ICE regimen) at intermediate dosage for advanced non-small cell lung cancer(NSCLC). J Chemother,1998,10(6)∶492-495.
  • 8[8]Chang AY, Asbury RF, Boros L, et al. Ifosfamide/carboplatin/etoposide chemotherapy in patients with metastatic non-small cell lung cancer. Semin Oncol,1995,22(3 Suppl 7)∶9-12.
  • 9[9]Hsieh RK, Chang AY, Boros L, et al. Phase Ⅱ study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer. Am J Clin Oncol,1994,17(6)∶509-513.

同被引文献14

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部